Quarterly ResultMay 8, 2026, 08:41 AM
Avenue Therapeutics Q1 Net Loss $(0.695)M; Faces Going Concern Doubt
AI Summary
Avenue Therapeutics, Inc. reported a net loss of $(695)k for the first quarter ended March 31, 2026, a significant reduction from $(1,858)k in the prior-year quarter, with net loss per share improving to $(0.21). Despite reduced operating expenses, the company's cash and cash equivalents declined to $2,417k, and its accumulated deficit grew to $(106.2) million. The company expressed substantial doubt about its ability to continue as a going concern, citing the need for additional funding. In February 2026, Avenue secured an exclusive worldwide license for ATX-04 for Pompe disease, but remains ineligible to use its Form S-3 and ATM facility following its Nasdaq delisting.
Key Highlights
- Net loss for Q1 2026 was $(695)k, down from $(1,858)k in Q1 2025.
- Net loss per common share was $(0.21) in Q1 2026, compared to $(0.62) in Q1 2025.
- Cash and cash equivalents decreased to $2,417k as of March 31, 2026.
- Operating expenses fell to $714k in Q1 2026 from $1,905k in Q1 2025.
- Accumulated deficit reached $(106.2) million as of March 31, 2026.
- Company faces substantial doubt about its ability to continue as a going concern.
- Secured exclusive worldwide license for ATX-04 in February 2026.
- Ineligible to use Form S-3 and ATM facility due to Nasdaq delisting.